Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Importance of Dyslipidaemia Treatment in Patients with Type 2 Diabetes Mellitus

Dominik Strikić
ORCID logo ,
Andro Vujević
* ORCID logo ,
Dražen Perica
ORCID logo ,
Dunja Leskovar
,
Kristina Paponja
,
Ivan Pećin
,
Iveta Merćep
ORCID logo
Version 1 : Received: 11 September 2023 / Approved: 12 September 2023 / Online: 13 September 2023 (02:57:55 CEST)

A peer-reviewed article of this Preprint also exists.

Strikić, D.; Vujević, A.; Perica, D.; Leskovar, D.; Paponja, K.; Pećin, I.; Merćep, I. Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review. Diabetology 2023, 4, 538-552. Strikić, D.; Vujević, A.; Perica, D.; Leskovar, D.; Paponja, K.; Pećin, I.; Merćep, I. Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review. Diabetology 2023, 4, 538-552.

Abstract

Type 2 diabetes mellitus (T2DM) is a common metabolic disease characterised by insulin resistance and elevated blood glucose levels, affecting millions of people worldwide. T2DM patients with dyslipidaemia have an increased risk of cardiovascular disease (CVD). A complex interplay of risk factors such as hyperglycaemia, dyslipidaemia, hypertension, obesity, inflammation and oxidative stress favour the development of atherosclerosis, a central mechanism in the pathogenesis of cardiovascular disease. Dyslipidaemia, a hallmark of T2DM, is characterised by elevated triglycerides, decreased high-density lipoprotein (HDL) cholesterol and the presence of small, dense low-density lipoprotein (LDL) particles, all of which promote atherosclerosis. In this article, we have attempted to present various treatment strategies that include pharmacological interventions such as statins, ezetimibe, PCSK9 inhibitors, fibrates and omega-3 fatty acids. We have also tried to highlight the pivotal role of lifestyle modifications, including physical activity and dietary changes, in improving lipid profiles and overall cardiovascular health in T2DM patients. We have also tried to present the latest clinical guidelines for the management of dyslipidaemia in T2DM patients. In conclusion, the treatment of dyslipidaemia in T2DM patients is of great importance as it lowers lipid particle levels, slows the progression of atherosclerosis and ultimately reduces susceptibility to cardiovascular disease.

Keywords

Type 2 diabetes mellitus; dyslipidaemia; metabolic disorder; pharmaceutical treatment; non-pharmaceutical treatment.

Subject

Medicine and Pharmacology, Endocrinology and Metabolism

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.